Ceribell Reports Third Quarter 2026 Financial Results

What happened

Ceribell reported third-quarter 2026 revenue of $29.3 million, up 30% year over year. It ended the quarter with 747 active accounts after adding 35 net new customers, reported double-digit growth in same-store utilization, and announced the full launch of its delirium monitoring solution.

Confirmed

Global impact / market context

More accounts and greater use at existing accounts can increase demand for Ceribell’s products, supporting revenue growth. The delirium solution’s full launch could add another source of sales, but the article does not report its revenue or how quickly hospitals will adopt it.

Analyst inference

Ceribell’s CEO described the core seizure business as a durable growth engine, while delirium monitoring has moved from a commercial pilot to full launch. The article also reports clearance for two EEG analysis functions, but provides no adoption, sales, or forward revenue figures.

Analyst inference

What to watch

1. Check later results for whether revenue growth continues and whether the 747 active accounts and record customer additions translate into sustained use and sales. Analyst inference
2. Look for reported uptake and revenue from the fully launched delirium monitoring solution; the article confirms launch but does not quantify customer demand or sales. Analyst inference
3. Track updates on the new hardware platform mentioned by the CEO, including its introduction timing and any reported effect on customer adoption or costs. Analyst inference

Evidence

• globenewswire.com